TherapeuticsMD Announces Third Quarter 2024 Financial Results
TherapeuticsMD, Inc. (“TherapeuticsMD” or the “Company”) (
NASDAQTXMD), a company that owns rights to pharmaceutical royalties, today reported financial results for the third quarter ended September 30, 2024.
TherapeuticsMD Announces Second Quarter 2024 Financial Results
TherapeuticsMD, Inc. (“TherapeuticsMD” or the “Company”) (
NASDAQTXMD), a company that owns rights to pharmaceutical royalties, today reported financial results for the second quarter ended June 30, 2024.
TherapeuticsMD Announces First Quarter 2024 Financial Results
TherapeuticsMD, Inc. (“TherapeuticsMD” or the “Company”) (
NASDAQTXMD), a company that owns rights to pharmaceutical royalties, today reported financial results for the first quarter ended March 31, 2024.
TherapeuticsMD Announces Full Year 2023 Financial Results
TherapeuticsMD, Inc. (“TherapeuticsMD” or the “Company”) (
NASDAQTXMD), a company that owns rights to pharmaceutical royalties, today reported financial results for the full year ended December 31, 2023.
TherapeuticsMD Announces Third Quarter 2023 Financial Results
TherapeuticsMD, Inc. (“TherapeuticsMD” or the “Company”) (
NASDAQTXMD), a company that owns rights to pharmaceutical royalties, today reported financial results for the third quarter ended September 30, 2023.
TherapeuticsMD Announces Second Quarter 2023 Financial Results
TherapeuticsMD, Inc. (“TherapeuticsMD” or the “Company”) (
NASDAQTXMD), a company that owns rights to pharmaceutical royalties, today reported financial results for the second quarter ended June 30, 2023.
TherapeuticsMD Announces First Quarter 2023 Financial Results
TherapeuticsMD, Inc. (“TherapeuticsMD” or the “Company”) (
NASDAQTXMD), a company that owns rights to pharmaceutical royalties, today reported financial results for the first quarter ended March 31, 2023.
TherapeuticsMD Announces Full Year 2022 Financial Results and Provides Update on Business Model Transition
TherapeuticsMD, Inc. (“TherapeuticsMD” or the “Company”) (
NASDAQTXMD), a company that owns rights to pharmaceutical royalties, today reported financial results for the full year ended December 31, 2022.
TherapeuticsMD Completes Transaction to License Its Products to Mayne Pharma
TherapeuticsMD, Inc. (
NASDAQTXMD) (“TherapeuticsMD,” “TXMD” or the “Company”), an innovative, leading women’s healthcare company, today announced that it has completed its previously announced transaction with Mayne Pharma Group Limited (“Mayne Pharma”), an ASX-listed specialty pharmaceutical company focused on commercializing novel and generic pharmaceuticals, pursuant to which TXMD granted Mayne Pharma an exclusive license to commercialize TXMD’s products in the United States. In addition, TXMD sold certain assets to Mayne Pharma to enable it to commercialize the products.
TherapeuticsMD Announces Definitive Agreements to License its Products to Mayne Pharma
TherapeuticsMD, Inc. (
NASDAQTXMD) (“TherapeuticsMD,” “TXMD” or the “Company”), an innovative, leading women’s healthcare company, today announced that it has entered into definitive agreements to license its products to an affiliate of Mayne Pharma Group Limited (“Mayne Pharma”), an ASX-listed specialty pharmaceutical company focused on commercializing novel and generic pharmaceuticals, for commercialization in the United States. In addition, TXMD has agreed to sell certain assets to Mayne Pharma to allow Mayne Pharma to commercialize the products.
TherapeuticsMD Announces Third Quarter 2022 Financial Results
TherapeuticsMD, Inc. (“TXMD” or the “Company”) (
NASDAQTXMD), an innovative, leading women’s healthcare company, today reported financial results for the third quarter ended September 30, 2022.
TherapeuticsMD Announces Additional $7 Million Private Placement
TherapeuticsMD, Inc. (
NASDAQTXMD), (“TherapeuticsMD” or the “Company”) an innovative, leading women’s healthcare company, announced today that it received an additional $7 million private investment in the Company’s Series A Preferred Stock from Rubric Capital Management LP. TherapeuticsMD expects to use the proceeds from the transaction for working capital.
TherapeuticsMD Announces $7 Million Private Placement
TherapeuticsMD, Inc. (
NASDAQTXMD), (“TherapeuticsMD” or the “Company”) an innovative, leading women’s healthcare company, announced today that it received a $7 million private investment in the Company’s Series A Preferred Stock from Rubric Capital Management LP (“Rubric”). TherapeuticsMD expects to use the proceeds from the transaction for working capital.
TherapeuticsMD Appoints Dr. Brian Bernick and Mr. Mark Glickman as Interim Co-Chief Executive Officers
TherapeuticsMD, Inc. (
NASDAQTXMD), (“TherapeuticsMD” or the “Company”) an innovative, leading women’s healthcare company, announced today the appointment of Dr. Brian Bernick and Mr. Mark Glickman as the Company’s Interim Co-Chief Executive Officers and Co-Principal Executive Officers. Dr. Bernick and Mr. Glickman succeed Mr. Hugh O’Dowd as the Company’s Chief Executive Officer.
TherapeuticsMD Announces Second Quarter 2022 Financial Results
TherapeuticsMD, Inc. (“TXMD” or the “Company”) (
NASDAQTXMD), an innovative, leading women’s healthcare company, today reported financial results for the Second Quarter ended June 30, 2022.
TherapeuticsMD to Report Second Quarter 2022 Financial Results on August 15, 2022
TherapeuticsMD, Inc. (“TXMD” or the “Company”) (
NASDAQTXMD), an innovative, leading women’s healthcare company, today announced that it will report its second quarter 2022 financial results on Monday, August 15, 2022, at 8:30 a.m. ET prior the opening of the U.S. financial markets.
TherapeuticsMD Secures $15 Million Equity Investment from Rubric Capital
TherapeuticsMD, Inc. (
NASDAQTXMD), (“TherapeuticsMD” or the “Company”) an innovative, leading women’s healthcare company, announced today that it has received a $15 million private investment in the Company’s common stock and a new series of preferred stock (“PIPE”) from Rubric Capital Management LP (“Rubric”). TherapeuticsMD expects to use the proceeds from the transaction to fulfill its near-term operating capital requirements.
TherapeuticsMD Announces Expiration of Tender Offer
TherapeuticsMD, Inc. (
NASDAQTXMD), (“TXMD” or the “Company”) an innovative, leading women’s healthcare company, announced today that Athene Merger, Inc., an affiliate of EW Healthcare Partners (“EW”), did not acquire the required majority of shares of TXMD through the previously announced tender offer by the extended offer deadline of one minute after 11:59 PM Eastern Time on July 12, 2022. As a result, the tender offer has expired according to its terms. The Company anticipates that the Merger Agreement between TXMD and EW will be terminated pursuant to its terms following 11:59 PM Eastern Time on July 13, 2022.
THERAPEUTICSMD INVESTOR ALERT by The Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of TherapeuticsMD, Inc. - TXMD
Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of TherapeuticsMD, Inc. (NasdaqGS: TXMD) to an affiliate of EW Healthcare Partners. Under the terms of the proposed transaction, shareholders of TherapeuticsMD will receive only $10.00 in cash for each share of TherapeuticsMD that they own. KSF is seeking to determine whether this consideration and the process that led to it are adequate, or whether the consideration undervalues the Company.
TXMD Stock Alert: Halper Sadeh LLP Is Investigating Whether the Sale of TherapeuticsMD, Inc. Is Fair to Shareholders
Halper Sadeh LLP, an investor rights law firm, is investigating whether the sale of TherapeuticsMD, Inc. (
NASDAQTXMD) to an affiliate of EW Healthcare Partners for $10.00 per share is fair to TherapeuticsMD shareholders.
TherapeuticsMD and EW Healthcare Partners Announce Definitive Agreement for EW Healthcare Partners to acquire TherapeuticsMD
TherapeuticsMD, Inc. (
NASDAQTXMD) (“TherapeuticsMD,” “TXMD” or the “Company”), an innovative, leading women’s healthcare company, today announced that it has entered into a definitive merger agreement to be acquired by an affiliate of EW Healthcare Partners, a private equity firm dedicated to making investments in rapidly growing healthcare companies.
TherapeuticsMD Receives U.S. Food and Drug Administration (FDA) Approval for Supplemental New Drug Application (sNDA) for ANNOVERA®
TherapeuticsMD, Inc. (
NASDAQTXMD) (“TXMD” or the “Company”), an innovative, leading women’s healthcare company, today announced the FDA’s approval of a supplemental New Drug Application (sNDA) for ANNOVERA. The sNDA included minor revisions to ANNOVERA’s in vitro release testing specification that allowed for normal manufacturing variability.
TherapeuticsMD Announces First Quarter 2022 Financial Results
TherapeuticsMD, Inc. (“TXMD” or the “Company”) (
NASDAQTXMD), an innovative, leading women’s healthcare company, today reported financial results for the first quarter ended March 31, 2022.
TherapeuticsMD to Report First Quarter 2022 Financial Results on May 16, 2022
TherapeuticsMD, Inc. (“TXMD” or the “Company”) (
NASDAQTXMD), an innovative, leading women’s healthcare company, today announced that it will report its first quarter 2022 financial results on Monday, May 16, 2022, after the closing of the U.S. financial markets.
TherapeuticsMD Completes the Divestiture of vitaCare Prescription Services to GoodRx in a Cash Transaction Valued at $150 Million
TherapeuticsMD, Inc. (
NASDAQTXMD), (“TXMD” or the “Company”) an innovative, leading women’s healthcare company, announced today the closing of the divestiture of vitaCare Prescription Services to GoodRx
NASDAQ: GDRXNASDAQGDRX)
